FDA’s 503B Bulks-List Decision on Tirzepatide: What It Means for Patients
Released: Last reviewed:
In April 2026 the FDA proposed to permanently keep tirzepatide off the list of ingredients that large-scale compounders may use. Here is a plain-language explanation of what was proposed, where it stands after the comment period, and what still remains legal.
Direct answer
On April 30, 2026, the FDA proposed to exclude tirzepatide — along with semaglutide and liraglutide — from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound these drugs from bulk substances. A public comment period closed June 29, 2026, and a final determination is pending as of July 9, 2026. If finalized as written, 503B outsourcing facilities could not bulk-compound tirzepatide under any circumstances — even if a new shortage were declared. Importantly, this proposal targets 503B bulk compounding; patient-specific 503A compounding with a documented clinical need is a separate pathway and is not eliminated by it.
What the 503B bulks list actually is
Outsourcing facilities registered under section 503B generally may compound from a bulk drug substance only when that substance is on the FDA’s 503B bulks list, or when the finished drug is on the FDA’s shortage list at the time of compounding. With tirzepatide no longer in shortage, neither condition is met. The proposal would settle the question permanently by determining that tirzepatide does not belong on the bulks list at all. For the difference between 503A pharmacies and 503B facilities, see our 503A vs 503B explainer.
What the FDA proposed on April 30, 2026
The agency announced it would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list after reviewing the nominations for these substances and not identifying a clinical need for outsourcing facilities to compound them from bulk. The FDA framed the move as protecting patients and preserving the drug-approval process while inviting public input through the federal docket. In short: when an FDA-approved product is available, the agency’s position is that large-scale compounding of a copy is not justified.
Where the timeline stands now (July 2026)
The public comment window closed on June 29, 2026. The FDA has said it will consider submitted comments before making a final determination, so as of this update the exclusion is proposed but not yet final. This sits at the end of a long sequence of actions: the FDA resolved the tirzepatide shortage in late 2024, 503A enforcement discretion ended February 18, 2025, and 503B enforcement discretion ended March 19, 2025. The 2026 proposal would close the remaining bulk pathway for good. For the fuller policy picture, see our 2026 GLP-1 compounding rules and post-shortage access articles.
What this changes for patients
The practical effect is on supply that flowed through 503B outsourcing facilities. As those pathways narrow, some telehealth programs have adjusted sourcing, emphasized patient-specific prescriptions, or stopped offering compounded tirzepatide altogether. If your medication has been arriving reliably each month from a large-scale compounder, this is the change most likely to affect you, and it is worth asking your provider directly how it is adapting.
What it does not change
Three things stay the same. First, patient-specific 503A compounding with a documented clinical need remains a lawful pathway and is not the target of this proposal. Second, compounded tirzepatide is still not FDA-approved and is not the same as Mounjaro or Zepbound. Third, brand-name tirzepatide — the FDA-approved route — is unaffected and is more broadly available now than during the shortage. If you are weighing options, our brand vs compounded comparison lays out the tradeoffs.
Why the FDA acted
The agency has pointed to patient-safety signals in its escalating posture: hundreds of adverse-event reports tied to compounded GLP-1s (more for semaglutide than tirzepatide), dosing errors from patients drawing doses out of multi-dose vials, and counterfeit products entering the market through online channels. The bulks-list proposal is the regulatory step that would make the current restriction durable rather than tied to shortage status.
What to verify with a provider right now
Ask any prospective provider three things: which pharmacy pathway it uses (503A patient-specific or 503B), how it is responding to the 2026 rules, and how it documents the clinical basis for your prescription. A confident, specific answer signals an operator tracking the landscape; vague or unchanged marketing that ignores the regulatory shift is a reason for extra scrutiny. Verify any certifications, such as LegitScript, independently, and confirm the provider can legally serve your state.
Recent changes
July 9, 2026: Published; regulatory status confirmed against the FDA proposal and the June 29 comment-period close.
April 30, 2026: FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list.
June 29, 2026: Public comment period closed; final determination pending.
Key takeaways
The FDA has proposed to permanently exclude tirzepatide from the 503B bulks list, and the comment period closed June 29, 2026, with a final rule still pending. If finalized, it ends large-scale 503B bulk compounding of tirzepatide even in a future shortage. Patient-specific 503A compounding with documented clinical need is a separate pathway and is not eliminated. Compounded tirzepatide remains not FDA-approved, while brand Mounjaro and Zepbound are unaffected and more available than before. Verify current status and a provider’s pathway directly rather than relying on any older summary.
FAQ
Does the 503B bulks-list proposal ban compounded tirzepatide entirely? No. The April 30, 2026 proposal targets bulk compounding by 503B outsourcing facilities. Patient-specific 503A compounding with a documented clinical need is a separate pathway and is not eliminated by this proposal.
Is the 503B exclusion final yet? Not as of July 2026. The FDA opened a public comment period that closed June 29, 2026, and the agency will consider the comments before issuing a final determination. Treat the status as pending and verify current status directly.
Could a future shortage reopen 503B compounding of tirzepatide? If the exclusion is finalized as written, it would foreclose that pathway even if a new shortage were declared, because it removes the bulks-list basis for outsourcing facilities. That is a key reason the proposal matters.
What should I do if my compounded tirzepatide comes from a 503B facility? Ask your provider which pharmacy pathway it uses and how it is responding to the current rules. A provider paying attention should be able to explain its sourcing and the clinical basis for your prescription in plain terms.
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Telehealth medications require evaluation and, when appropriate, a prescription from a licensed clinician. Regulatory status can change; confirm current FDA status, pricing, state availability, and pharmacy details directly before acting.